healthcare-thumbnail.png

Colorectal Cancer Market Research Report

Published: 2025 - January

Report Code: VMR-1121

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Colorectal Cancer Market Analysis

The colorectal cancer market encompasses a wide array of therapeutics and diagnostic solutions designed to address one of the most prevalent malignancies globally. Colorectal cancer includes malignancies affecting the colon or rectum, with treatment approaches evolving rapidly due to advances in targeted therapies, immunotherapies, and personalized medicine. This market is driven by breakthroughs in molecular diagnostics, biomarkers, and innovative therapies tailored to genetic mutations, including KRAS, NRAS, and BRAF mutations.

Disruptive Impact and Opportunities:

The market has witnessed disruptive growth, with novel drug development transforming treatment paradigms. Emerging therapies like adagrasib and etrumadenant exemplify innovation, targeting previously untreatable mutations or pathways. The rise of liquid biopsies and precision diagnostics has streamlined early detection, making solutions more accessible, reliable, and impactful. The shift toward targeted and immune-based therapies promises safer and more effective treatments, reducing the reliance on traditional cytotoxic chemotherapy. This creates significant opportunities in a market projected for substantial growth due to the unmet clinical needs, aging population, and rising incidence rates.

Colorectal Cancer Market Segmentaton - Emerging Drugs

  • Adagrasib

  • XL092

  • EO2040

  • Etrumadenant

  • LYL845

Colorectal Cancer Market Segmentaton - Marketed Drugs

  • Keytruda (pembrolizumab) injection

  • Stivarga (Regorafenib)

  • Jemperli (dostarlimab)

  • Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib)

Key Companies:

  • Mirati Therapeutics

  • Exelixis, Enterome

  • Arcus Biosciences

  • Lyell Immunopharma

  • AstraZeneca

  • Novartis Pharmaceuticals

  • Surgimab

  • Numab Therapeutics

  • SOTIO Biotech

  • Amgen

Colorectal Cancer Market Segmentaton - By Type

·  Therapeutics

  • Chemotherapy

    • 5-Fluorouracil (5-FU)

    • Capecitabine

    • Oxaliplatin

    • Irinotecan

  • Targeted Therapy

    • VEGF Inhibitors

      • Bevacizumab

      • Aflibercept

    • EGFR Inhibitors

      • Cetuximab

      • Panitumumab

    • BRAF Inhibitors

      • Encorafenib

    • HER2 Inhibitors

      • Trastuzumab

      • Pertuzumab

  • Immunotherapy

    • PD-1 Inhibitors

      • Nivolumab

      • Pembrolizumab

    • CTLA-4 Inhibitors

      • Ipilimumab

  • Hormonal Therapy (if applicable in specific subtypes)

·  Diagnostics

  • Biomarker Testing

    • KRAS Mutation Testing

    • NRAS Mutation Testing

    • BRAF Mutation Testing

    • Microsatellite Instability (MSI) Testing

  • Imaging Modalities

    • CT Scans

    • MRI

    • PET-CT

  • Liquid Biopsy

  • Colonoscopy

Colorectal Cancer Market Segmentaton -  By Administration Type

· Oral

  • Capecitabine

  • Trifluridine/Tipiracil

· Intravenous (IV)

  • Chemotherapy Agents

    • 5-Fluorouracil

    • Oxaliplatin

    • Irinotecan

  • Targeted Therapies

    • Bevacizumab

    • Cetuximab

    • Panitumumab

  • Immunotherapies

    • Nivolumab

    • Pembrolizumab

  • Combination Therapies

· Injectable (Non-IV)

What’s in It for You?

  • Insights into market trends and growth drivers to identify investment opportunities.

  • Detailed analysis of emerging and marketed therapies for competitive benchmarking.

  • Strategic guidance on partnerships and collaborations with key players.

  • Assessment of unmet clinical needs and opportunities for innovation.

  • A comprehensive overview of market dynamics to shape business strategies.

Colorectal Cancer Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Colorectal Cancer Market - Executive Summary                                           

               1.1. Introduction                             

               1.2. Objectives                 

               1.3. Key Findings                             

                              1.3.1. Market Size 2022 & 2032: By Key Country (10MM)

                              1.3.2. Global Market Size 2022 & 2032: By Key Segment  

                              1.3.3. Key Investments & Startup Analysis             

               1.4. Research Methodology                           

2. Understanding the Disease                                   

               2.1. Disease Overview                   

               2.2. Classification                            

               2.3. Signs and Symptoms                             

               2.4. Risk Factors              

               2.5. Causes                       

               2.6. Disease Biology & Digital Innovations                            

               2.7. Stages & Staging System                     

               2.8. Diagnostic Algorithm                            

               2.9. Current Treatment Practices & Algorithm                     

               2.10. Current Standard of Care and Treatment Gaps                        

               2.11. Patient Demographics and Treatment Pathways                     

3. Guidelines                                                                                 

4. Unmet Needs                                            

5. Epidemiology and Patient Population                                

               5.1. Epidemiology Key Findings                  

               5.2. Assumptions and Rationale: 10MM                

               5.3. Epidemiology Scenario: 10MM                         

               5.4. U.S. Epidemiology Scenario                

               5.5. EU-5 Epidemiology                 

                              5.5.1. U.K. Epidemiology Scenario            

                              5.5.2. Germany Epidemiology Scenario   

                              5.5.3. France Epidemiology Scenario       

                              5.5.4. Italy Epidemiology Scenario            

                              5.5.5. Spain Epidemiology Scenario          

               5.6. Japan Epidemiology Scenario                            

               5.7. China Epidemiology Scenario                            

               5.8. Australia Epidemiology Scenario                      

               5.9. India Epidemiology Scenario                                            

6. Real-world Data & Real-world Evidence                                           

7. Drug Development Landscape                                            

               7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies                    

                              7.1.1. FRUZAQLA (fruquintinib) - Takeda 

                                             7.1.1.1. Product Description

                                             7.1.1.2. Regulatory Milestones

                                             7.1.1.3. Other Developmental Activities

                                             7.1.1.4. Pivotal Clinical Trials

                                             7.1.1.5. Ongoing Current Pipeline Activity

                              7.1.2. TUKSYA (tucatinib) - Genentech/Seagen     

                                             7.1.2.1. Product Description

                                             7.1.2.2. Regulatory Milestones

                                             7.1.2.3. Other Developmental Activities

                                             7.1.2.4. Pivotal Clinical Trials

                                             7.1.2.5. Ongoing Current Pipeline Activity

                              7.1.3. ENHERTU (trastuzumab deruxtecan) - AstraZeneca/Daiichi Sankyo 

                                             7.1.3.1. Product Description

                                             7.1.3.2. Regulatory Milestones

                                             7.1.3.3. Other Developmental Activities

                                             7.1.3.4. Pivotal Clinical Trials

                                             7.1.3.5. Ongoing Current Pipeline Activity

                              7.1.4. KEYTRUDA (pembrolizumab) - Merck          

                                             7.1.4.1. Product Description

                                             7.1.4.2. Regulatory Milestones

                                             7.1.4.3. Other Developmental Activities

                                             7.1.4.4. Pivotal Clinical Trials

                                             7.1.4.5. Ongoing Current Pipeline Activity

               7.2. Competitive Analysis and Differentiation                      

               7.3. Overview of Similar/Competing Drugs in Clinical Trials                           

               7.4. Future Trends and Emerging Drugs                 

                              7.4.1. Favezelimab + pembrolizumab - Merck      

                                             7.4.1.1. Product Description

                                             7.4.1.2. Clinical Development

                                             7.4.1.3. Safety and Efficacy

                              7.4.2. LUMAKRAS (sotorasib) - Amgen     

                                             7.4.2.1. Product Description

                                             7.4.2.2. Clinical Development

                                             7.4.2.3. Safety and Efficacy

                              7.4.3. Onvansertib - Cardiff Oncology       

                                             7.4.3.1. Product Description

                                             7.4.3.2. Clinical Development

                                             7.4.3.3. Safety and Efficacy

                              7.4.4. Nibrozetone (RRx-001) - EpicentRx              

                                             7.4.4.1. Product Description

                                             7.4.4.2. Clinical Development

                                             7.4.4.3. Safety and Efficacy

8. Regulatory Strategy and Potential Challenges                                

               8.1. Regulatory Pathways in Key Markets                             

               8.2. Anticipated Regulatory Hurdles and Mitigation Strategies                     

               8.3. Case Studies in Oncology Drug Regulation                    

               8.4. Impact of Potential Changes to Regulatory Framework                          

9. Commercial Landscape                                          

               9.1. Market Size & Growth Rates                             

               9.2. Key Approvals & Anticipated Loss of Exclusivity                         

               9.3. PESTLE & Porter’s Five Forces Analysis                          

               9.4. Market Shares, Positioning/Ranking                

               9.5. Market Drivers                        

               9.6. Identification of Threats                      

               9.7. Digital Evolution in Commercialization                           

10. Market Segmentation                                           

               10.1. Market by Treatment                         

                              10.1.1. Chemotherapy   

                              10.1.2. Targeted Therapy             

                              10.1.3. Radiation Therapy            

                              10.1.4. Surgery  

                              10.1.5. Immunotherapy 

                              10.1.6. Embolization       

                              10.1.7. Others   

               10.2. Market by Route of Administration                

                              10.2.1. Oral       

                              10.2.2. Parenteral           

                              10.2.3. Others   

11. Pricing, Reimbursement, and Access                              

               11.1. Competitive Pricing Analysis                           

               11.2. Reimbursement Landscape and Challenges               

               11.3. Strategies for Market Access and Equity                     

               11.4. Patient Spending/Expenditure Analysis                      

12. Future Trends, Disruptions, and Opportunities                                           

               12.1. Analysis of Emerging Trends                           

               12.2. Technological Impact                         

               12.3. Impact of Potential Market Disruptors                        

               12.4. Opportunities for Future Development and Expansion                         

               12.5. Considerations for Investment Opportunities                           

13. Global Market Dynamics                                     

               13.1. Regional Regulatory Disparities                      

               13.2. Cross-Border Partnership Strategies                            

               13.3. Global Supply Chain Dynamics                       

               13.4. Case Studies: Success and Failure in Global Markets                             

               13.5. Strategies for Global Expansion and Localization                     

14. Company Profiles                                   

               14.1. AstraZeneca                          

               14.2. Novartis Pharmaceuticals                 

               14.3. Pfizer                       

               14.4. Takeda                     

               14.5. Bristol-Myers Squibb                          

               14.6. Amgen                     

               14.7. Mirati Therapeutics                            

               14.8. Lyell Immunopharma                          

               14.9. SOTIO Biotech                       

               14.10. Baili Pharmaceutical                         

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.